KEYNOTE-119: Phase 3 study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple-negative breast cancer (mTNBC) - Cortés, J; Lipatov, O; Im, S (Ann Oncol, 2019)
et al.